North America Tissue Diagnostics Market Size, Trends and Insights By Technology (In Situ Hybridization, Immunohistochemistry, Digital Pathology and workflow, Primary and Special Staining, Anatomic Pathology), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Other Cancer), By End Users (Research Laboratories, Hospitals, Contract Research Organizations (CROs), Pharmaceutical Organizations) and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | North America |
| Largest Market: | North America |
Major Players
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Others
Reports Description
As per the current market research conducted by the CMI Team, the North America Tissue Diagnostics Market is expected to record a CAGR of 7% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 2.5 Billion. By 2032, the valuation is anticipated to reach USD 4.7 Billion.
The North America Tissue Diagnostics Market encompasses the industry involved in the diagnosis of diseases through the examination of tissues. It includes a range of diagnostic methods, such as histology, cytology, and immunohistochemistry, to analyze tissue samples for identifying abnormalities and diseases.
Key players in this market provide diagnostic tools, equipment, and services, contributing to advancements in personalized medicine, early disease detection, and precision diagnostics.
Factors influencing the market include technological innovations, a focus on automation, and a growing aging population. The market plays a pivotal role in improving healthcare outcomes by enabling accurate and timely diagnoses for effective patient care.
North America Tissue Diagnostics Market – Significant Growth Factors
The North America Tissue Diagnostics Market presents significant growth opportunities due to several factors:
- Technological Advancements: Continuous innovations in diagnostic technologies, including advanced imaging techniques and automation, drive the growth of the tissue diagnostics market by enhancing accuracy and efficiency in disease detection.
- Increasing Incidence of Chronic Diseases: The rising prevalence of chronic diseases, such as cancer, fuels the demand for tissue diagnostics as it plays a crucial role in early detection and precise diagnosis, contributing to improved treatment outcomes.
- Aging Population: The demographic shift towards an aging population in North America is a significant driver, leading to a higher incidence of age-related diseases and an increased demand for tissue diagnostics for effective disease management.
- Rising Awareness and Patient Demand: Growing awareness among patients about the importance of early diagnosis and personalized medicine boosts the demand for tissue diagnostics services, prompting healthcare providers to expand their offerings.
- Telehealth Integration: The increasing adoption of telehealth services presents an opportunity to integrate tissue diagnostics into remote healthcare delivery, enhancing accessibility to diagnostic services and improving patient outcomes.
- Collaboration and Research Opportunities: Collaborations between industry players and research institutions present opportunities for developing and implementing innovative diagnostic solutions, fostering advancements in tissue diagnostics for improved patient care.
- Government Initiatives and Funding: Supportive government initiatives, including funding for healthcare infrastructure and research projects, act as a driver for the tissue diagnostics market. Increased financial backing and favorable policies create an environment conducive to innovation and market expansion.
- Collaborations and Strategic Partnerships: Collaborative efforts between healthcare institutions, diagnostic companies, and technology firms drive market growth. Strategic partnerships facilitate the development of integrated solutions, combining diagnostic technologies with healthcare systems, thereby enhancing the overall efficiency and accessibility of tissue diagnostics services.
North America Tissue Diagnostics Market – Mergers and Acquisitions
The North America Tissue Diagnostics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the North America Tissue Diagnostics Market include:
- In 2023, Agilent Technologies, Inc. partnered with Akoya Biosciences, Inc. to co-develop multiplex immunohistochemistry (IHC) diagnostic solutions. This collaboration aims to commercialize workflow solutions for multiplex assays in tissue analysis, offering an advanced multiplex IHC solution for biomarker clinical research, leveraging the capabilities of digital pathology.
- In 2021, Roche introduced the DISCOVERY Green HRP Chromogen Detection Kit, aiming to broaden immunohistochemistry multiplexing capabilities in cancer research. This kit enhances the detection of multiple biomarkers simultaneously, facilitating more comprehensive and detailed analysis in the field of cancer diagnostics and research.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the North America Tissue Diagnostics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| North America Tissue Diagnostics Market | India Hospital Furniture Market | India IVF Services Market |
| CAGR 7% (Approx) | CAGR 9.23% (Approx) | CAGR 16.23% (Approx) |
| USD 4.7 Billion by 2032 | USD 909.6 Million by 2032 | USD 5,051.3 Million by 2032 |
North America Tissue Diagnostics Market – Significant Threats
The North America Tissue Diagnostics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Regulatory Challenges: Evolving and stringent regulatory requirements in the healthcare sector pose a significant threat to the North America Tissue Diagnostics Market. Compliance with changing regulations may increase operational costs and create hurdles in product approvals and market entry.
- High Implementation Costs: The initial costs associated with implementing advanced tissue diagnostic technologies and maintaining up-to-date equipment can be substantial. This financial barrier may limit the adoption of advanced diagnostic solutions, especially for smaller healthcare facilities, impacting market growth.
- Data Security Concerns: The increasing reliance on digital platforms and electronic health records raises concerns about data security and patient privacy. Cybersecurity threats and data breaches can undermine confidence in tissue diagnostics technologies, potentially affecting market acceptance and adoption.
- Supply Chain Disruptions: The tissue diagnostics market relies on a complex global supply chain for reagents, equipment, and consumables. Disruptions in the supply chain, whether due to geopolitical events, natural disasters, or global health crises, can adversely impact the availability of essential components, leading to market constraints.
- Competition from Alternative Diagnostic Methods: Emerging alternative diagnostic methods, such as liquid biopsies and molecular diagnostics, pose a threat to traditional tissue diagnostics. These alternatives offer less invasive approaches, potentially diverting demand away from traditional tissue-based diagnostic methods and affecting market share.
Category-Wise Insights
By Technology:
- In Situ Hybridization (ISH): In Situ Hybridization involves detecting specific DNA or RNA sequences in tissue sections. In North America, ISH is witnessing increased adoption of precise genetic analysis in cancer. Trends include expanded use in molecular pathology, aiding targeted therapies, and its application in personalized medicine.
- Immunohistochemistry (IHC): Immunohistochemistry identifies antigens in tissues using antibodies. In North America, IHC is pivotal for cancer diagnosis. Trends include automation for efficiency, biomarker discovery, and its integral role in companion diagnostics for targeted therapies.
- Digital Pathology and Workflow: Digital Pathology employs digital tools for managing and interpreting pathology information. In North America, it’s evolving with trends in AI integration, remote diagnostics, and enhanced collaboration, improving diagnostic accuracy and streamlining workflows for pathologists.
- Primary and Special Staining: Primary and Special Staining involve coloration of tissues for microscopic examination. In North America, these traditional methods persist. Trends include automation for efficiency, standardization for reproducibility, and novel stains for enhanced diagnostic information.
- Anatomic Pathology: Anatomic Pathology focuses on studying tissues for disease diagnosis. In North America, trends include increasing demand for subspecialty expertise, technological integration for efficiency, and a growing role in personalized medicine advancements.
By Application
- Prostate Cancer: Prostate cancer tissue diagnostics involve examining prostate tissue for cancerous abnormalities. Trends in North America include the increasing adoption of multiparametric magnetic resonance imaging (mpMRI) for precise diagnoses and the development of biomarkers, enhancing early detection and personalized treatment strategies.
- Breast Cancer: Breast cancer tissue diagnostics analyze breast tissue for malignancies. North America sees a trend towards advanced molecular testing, like HER2/neu testing and gene expression profiling. This aids in accurate subtype identification, guiding targeted therapies and improving overall breast cancer management.
- Lung Cancer: Tissue diagnostics for lung cancer involve analyzing lung tissue for abnormalities. In North America, a trend involves the integration of liquid biopsy techniques alongside traditional tissue biopsies for comprehensive genetic profiling. This enhances early detection and treatment decisions for lung cancer.
- Gastric Cancer: Gastric cancer tissue diagnostics focus on examining stomach tissue for cancer. In North America, a trend includes the application of immunohistochemistry and molecular testing to identify specific markers, guiding personalized treatment approaches. This enhances diagnostic accuracy and treatment planning for gastric cancer.
- Other Cancer: Tissue diagnostics for various cancers beyond the specified categories involve analyzing tissue samples for malignancies. Trends include the integration of artificial intelligence in pathology for faster and more accurate diagnoses, contributing to improved patient outcomes and personalized treatment strategies.
By End User
- Research Laboratories: Research laboratories in North America Tissue Diagnostics Market conduct in-depth studies to develop and enhance diagnostic technologies. Trends include a focus on molecular diagnostics, automation for efficiency, and collaborative projects with industry players to advance diagnostic capabilities.
- Hospitals: Hospitals are crucial end-users in the Tissue Diagnostics Market, providing diagnostic services to patients. Trends include the integration of digital pathology, point-of-care diagnostics, and a shift towards personalized medicine for more effective patient care.
- Contract Research Organizations (CROs): Contract Research Organizations play a pivotal role in clinical research and drug development, utilizing tissue diagnostics for robust trial outcomes. Trends involve increased outsourcing of diagnostic services, adoption of advanced imaging techniques, and customization of diagnostic solutions for research studies.
- Pharmaceutical Organizations: Pharmaceutical organizations leverage tissue diagnostics to enhance drug development and clinical trials. Trends include a growing emphasis on companion diagnostics, biomarker identification for targeted therapies, and collaborations with diagnostic companies to streamline the drug development process.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 2.5 Billion |
| Projected Market Size in 2032 | USD 4.7 Billion |
| Market Size in 2022 | USD 2.4 Billion |
| CAGR Growth Rate | 7% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Technology, Application, End Users and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Competitive Landscape – North America Tissue Diagnostics Market
The North America Tissue Diagnostics Market is highly competitive, with a large number of manufacturers and retailers operating. Some of the key players in the market include:
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becton Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
Emerging players such as Guardant Health and Foundation Medicine are adopting innovation to enter the North America Tissue Diagnostics Market. They focus on liquid biopsy technologies, next-generation sequencing, and artificial intelligence for enhanced diagnostic precision and efficiency, catering to evolving healthcare demands.
Established leaders like Roche Diagnostics, Thermo Fisher Scientific, and Danaher Corporation dominate the North America Tissue Diagnostics Market. Their market dominance is attributed to extensive R&D, diverse product portfolios, strategic acquisitions, and strong collaborations, ensuring a comprehensive and technologically advanced suite of tissue diagnostic solutions.
The North America Tissue Diagnostics Market is segmented as follows:
By Technology
- In Situ Hybridization
- Consumables
- Instruments
- Software
- Immunohistochemistry
- Instruments
- Slide Staining Systems
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Other Products
- Consumables
- Antibodies
- Reagents
- Kits
- Instruments
- Digital Pathology and workflow
- Whole Slide Imaging
- Image Analysis Informatics
- Information Management System Storage & Communication
- Primary and Special Staining
- Anatomic Pathology
- Instruments
- Microtomes & Cryostat Microtomes
- Tissue Processors
- Automatic Strainers
- Other Products
- Consumables
- Reagents & Antibodies
- Probes & Kits
- Others
By Application
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Other Cancer
By End Users
- Research Laboratories
- Hospitals
- Contract Research Organizations (CROs)
- Pharmaceutical Organizations
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 North America Tissue Diagnostics Market, (2024 – 2033) (USD Billion)
- 2.2 North America Tissue Diagnostics Market: snapshot
- Chapter 3. North America Tissue Diagnostics Market – Industry Analysis
- 3.1 North America Tissue Diagnostics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Technological Advancements
- 3.2.2 Increasing Incidence of Chronic Diseases
- 3.2.3 Aging Population
- 3.2.4 Rising Awareness and Patient Demand
- 3.2.5 Telehealth Integration
- 3.2.6 Collaboration and Research Opportunities
- 3.2.7 Government Initiatives and Funding.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End Users
- Chapter 4. North America Tissue Diagnostics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 North America Tissue Diagnostics Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. North America Tissue Diagnostics Market – Technology Analysis
- 5.1 North America Tissue Diagnostics Market Overview: By Technology
- 5.1.1 North America Tissue Diagnostics Market Share, By Technology, 2022 and – 2033
- 5.2 In Situ Hybridization
- 5.2.1 North America Tissue Diagnostics Market by In Situ Hybridization, 2024 – 2033 (USD Billion)
- 5.3 Consumables
- 5.3.1 North America Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Billion)
- 5.4 Instruments
- 5.4.1 North America Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Billion)
- 5.5 Software
- 5.5.1 North America Tissue Diagnostics Market by Software, 2024 – 2033 (USD Billion)
- 5.6 Immunohistochemistry
- 5.6.1 North America Tissue Diagnostics Market by Immunohistochemistry, 2024 – 2033 (USD Billion)
- 5.7 Instruments
- 5.7.1 North America Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Billion)
- 5.8 Slide Staining Systems
- 5.8.1 North America Tissue Diagnostics Market by Slide Staining Systems, 2024 – 2033 (USD Billion)
- 5.9 Tissue Microarrays
- 5.9.1 North America Tissue Diagnostics Market by Tissue Microarrays, 2024 – 2033 (USD Billion)
- 5.10 Tissue Processing Systems
- 5.10.1 North America Tissue Diagnostics Market by Tissue Processing Systems, 2024 – 2033 (USD Billion)
- 5.11 Slide Scanners
- 5.11.1 North America Tissue Diagnostics Market by Slide Scanners, 2024 – 2033 (USD Billion)
- 5.12 Other Products
- 5.12.1 North America Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Billion)
- 5.13 Consumables
- 5.13.1 North America Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Billion)
- 5.14 Antibodies
- 5.14.1 North America Tissue Diagnostics Market by Antibodies, 2024 – 2033 (USD Billion)
- 5.15 Reagents
- 5.15.1 North America Tissue Diagnostics Market by Reagents, 2024 – 2033 (USD Billion)
- 5.16 Kits
- 5.16.1 North America Tissue Diagnostics Market by Kits, 2024 – 2033 (USD Billion)
- 5.17 Digital Pathology and Workflow
- 5.17.1 North America Tissue Diagnostics Market by Digital Pathology and Workflow, 2024 – 2033 (USD Billion)
- 5.18 Whole Slide Imaging
- 5.18.1 North America Tissue Diagnostics Market by Whole Slide Imaging, 2024 – 2033 (USD Billion)
- 5.19 Image Analysis Informatics
- 5.19.1 North America Tissue Diagnostics Market by Image Analysis Informatics, 2024 – 2033 (USD Billion)
- 5.20 Information Management System Storage & Communication
- 5.20.1 North America Tissue Diagnostics Market by Information Management System Storage & Communication, 2024 – 2033 (USD Billion)
- 5.21 Primary and Special Staining
- 5.21.1 North America Tissue Diagnostics Market by Primary and Special Staining, 2024 – 2033 (USD Billion)
- 5.22 Anatomic Pathology
- 5.22.1 North America Tissue Diagnostics Market by Anatomic Pathology, 2024 – 2033 (USD Billion)
- 5.23 Instruments
- 5.23.1 North America Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Billion)
- 5.24 Microtomes & Cryostat Microtomes
- 5.24.1 North America Tissue Diagnostics Market by Microtomes & Cryostat Microtomes, 2024 – 2033 (USD Billion)
- 5.25 Tissue Processors
- 5.25.1 North America Tissue Diagnostics Market by Tissue Processors, 2024 – 2033 (USD Billion)
- 5.26 Automatic Strainers
- 5.26.1 North America Tissue Diagnostics Market by Automatic Strainers, 2024 – 2033 (USD Billion)
- 5.27 Other Products
- 5.27.1 North America Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Billion)
- 5.28 Consumables
- 5.28.1 North America Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Billion)
- 5.29 Reagents & Antibodies
- 5.29.1 North America Tissue Diagnostics Market by Reagents & Antibodies, 2024 – 2033 (USD Billion)
- 5.30 Probes & Kits
- 5.30.1 North America Tissue Diagnostics Market by Probes & Kits, 2024 – 2033 (USD Billion)
- 5.31 Others
- 5.31.1 North America Tissue Diagnostics Market by Others, 2024 – 2033 (USD Billion)
- 5.1 North America Tissue Diagnostics Market Overview: By Technology
- Chapter 6. North America Tissue Diagnostics Market – Application Analysis
- 6.1 North America Tissue Diagnostics Market Overview: By Application
- 6.1.1 North America Tissue Diagnostics Market Share, By Application, 2022 and – 2033
- 6.2 Prostate Cancer
- 6.2.1 North America Tissue Diagnostics Market by Prostate Cancer, 2024 – 2033 (USD Billion)
- 6.3 Breast Cancer
- 6.3.1 North America Tissue Diagnostics Market by Breast Cancer, 2024 – 2033 (USD Billion)
- 6.4 Lung Cancer
- 6.4.1 North America Tissue Diagnostics Market by Lung Cancer, 2024 – 2033 (USD Billion)
- 6.5 Gastric Cancer
- 6.5.1 North America Tissue Diagnostics Market by Gastric Cancer, 2024 – 2033 (USD Billion)
- 6.6 Other Cancer
- 6.6.1 North America Tissue Diagnostics Market by Other Cancer, 2024 – 2033 (USD Billion)
- 6.1 North America Tissue Diagnostics Market Overview: By Application
- Chapter 7. North America Tissue Diagnostics Market – End Users Analysis
- 7.1 North America Tissue Diagnostics Market Overview: By End Users
- 7.1.1 North America Tissue Diagnostics Market Share, By End Users, 2022 and – 2033
- 7.2 Research Laboratories
- 7.2.1 North America Tissue Diagnostics Market by Research Laboratories, 2024 – 2033 (USD Billion)
- 7.3 Hospitals
- 7.3.1 North America Tissue Diagnostics Market by Hospitals, 2024 – 2033 (USD Billion)
- 7.4 Contract Research Organizations (CROs)
- 7.4.1 North America Tissue Diagnostics Market by Contract Research Organizations (CROs), 2024 – 2033 (USD Billion)
- 7.5 Pharmaceutical Organizations
- 7.5.1 North America Tissue Diagnostics Market by Pharmaceutical Organizations, 2024 – 2033 (USD Billion)
- 7.1 North America Tissue Diagnostics Market Overview: By End Users
- Chapter 8. North America Tissue Diagnostics Market – Regional Analysis
- 8.1 North America Tissue Diagnostics Market Regional Overview
- 8.2 North America Tissue Diagnostics Market Share, by Region, 2022 & – 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America North America Tissue Diagnostics Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America North America Tissue Diagnostics Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America North America Tissue Diagnostics Market, 2024 – 2033 (USD Billion)
- 8.4 North America North America Tissue Diagnostics Market, by Technology, 2024 – 2033
- 8.4.1 North America North America Tissue Diagnostics Market, by Technology, 2024 – 2033 (USD Billion)
- 8.5 North America North America Tissue Diagnostics Market, by Application, 2024 – 2033
- 8.5.1 North America North America Tissue Diagnostics Market, by Application, 2024 – 2033 (USD Billion)
- 8.6 North America North America Tissue Diagnostics Market, by End Users, 2024 – 2033
- 8.6.1 North America North America Tissue Diagnostics Market, by End Users, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 Roche Diagnostics Corporation
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Thermo Fisher Scientific Inc.
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Abbott Laboratories
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Danaher Corporation
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Agilent Technologies Inc.
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Bio-Rad Laboratories Inc.
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Siemens Healthineers
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Leica Biosystems Nussloch GmbH
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Becton Dickinson and Company (BD)
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Sysmex Corporation
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Illumina Inc.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 PerkinElmer Inc.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Merck KGaA
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Cell Signaling Technology Inc.
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 Hologic Inc.
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 Others.
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.1 Roche Diagnostics Corporation
List Of Figures
Figures No 1 to 51
List Of Tables
Tables NO 1 to 5
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becton, Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Others
FAQs
The key factors driving the Market are Technological Advancements, Increasing Incidence of Chronic Diseases, Aging Population, Rising Awareness and Patient Demand, Telehealth Integration, Collaboration and Research Opportunities And Government Initiatives and Funding.
The “In Situ Hybridization” category dominated the market in 2022.
The key players in the market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Siemens Healthineers, Leica Biosystems Nussloch GmbH , Becton, Dickinson and Company (BD), Sysmex Corporation, Illumina Inc., PerkinElmer Inc., Merck KGaA, Cell Signaling Technology Inc., Hologic Inc., Others.
The global market is projected to grow at a CAGR of 7% during the forecast period, 2023-2032.
The North America Tissue Diagnostics Market size was valued at USD 2.5 Billion in 2023.